Psychiatry

The agency did not find any efficacy or safety issues regarding the potential treatment for adults with schizophrenia or bipolar I disorder.

The study authors noted that dementia prevention could become a compelling indication for older individuals receiving antihypertensive treatment.

Nightware provides vibrations when it senses the user is having a nightmare.

Supernus indicates no efficacy or safety concerns from their pediatric ADHD medication.

A greater number of cumulative days of montelukast use did not increase the risk of ADHD in these patients.

Researchers have been unable to leverage new technology for ADHD screening.

Dr. David Goodman discusses the gaps in ADHD treatment.

Researchers find 1 lipid class and 6 miRNAs differed significantly between different treatment groups.

It is possible to diagnose patients with ADHD as young as 2 years old.

AXS-05 significantly relieved agitation, demonstrating a change from baseline in the CMAI total score of 15.4 compared to 11.5 for the placebo.

Treatment for ADHD is similar for adolescents and adult patients.

Dr. David Goodman will present 5 times during NEI about different ADHD issues and topics.

A large portion of communication is non-verbal.

Clinicians rated 82% of the patients receiving the study drug and 46% in the placebo group as either much improved or very much improved on the Clinical Global Impression of Improvement scale.

Attempts to use neuroimaging to screen for ADHD in the past have failed.

Both methylphenidate PRC-063 and lisdexamfetamine led to improved performances for drivers with ADHD.

The findings of this multicenter cohort may have implications for diagnosis, prognosis, and disease monitoring, as well as for clinical trials targeting disease-specific proteins in DLB.

Precision medicine could have a major impact in ADHD.

ADHD is associated with increased procedures, including blood transfusions, hospital admissions, and emergency department visits.

Screenings for ADHD have not improved in several years.

Medications in psychiatry are often ineffective for patients.

Only 29.5% of sampled CBD users claimed any wellness benefit.

Dr. Cortese discusses how new research can drive changes to ADHD clinical trials.

The younger generation is able to adapt to new technology for therapy better than previous generations.

Cataracts, but not AMD or glaucoma, were associated with an increased risk of depressive symptoms in the elderly in a prospective long-term study.